ישראל - עברית - Ministry of Health

bayer israel ltd - cyproterone acetate - טבליה - cyproterone acetate 50 mg - cyproterone - cyproterone - for antiandrogen therapy in men: sexual disorders, inoperable prostatic carcinoma.

ישראל - עברית - Ministry of Health

bayer israel ltd - cyproterone acetate - טבליה - cyproterone acetate 10 mg - cyproterone - cyproterone - anti androgen for moderate and severe signs of androgenization in the women.

ישראל - עברית - Ministry of Health

bayer israel ltd - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 35 mcg; cyproterone acetate 2 mg - cyproterone and estrogen - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.

ישראל - עברית - Ministry of Health

bayer israel ltd - sorafenib as tosylate - טבליות מצופות פילם - sorafenib as tosylate 200 mg - sorafenib - sorafenib - nexavar is indicated for the treatment of patients with advanced renal cell carcinoma. treatment of patients with hepatocellular carcinoma.

ישראל - עברית - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

ישראל - עברית - Ministry of Health

bayer israel ltd - clodronic acid disodium 60 mg/ml - concentrate for solution for infusion - clodronic acid - treatment of hypercalcemia due to malignancy and treatment of osteolytic bone metastatses in connection with conventional cancer therapy.

ישראל - עברית - Ministry of Health

bayer israel ltd - clodronic acid disodium 800 mg - film coated tablets - clodronic acid - treatment of hypercalcemia due to malignancy. palliative treatment of osteolysis due to malignancy.

ישראל - עברית - Ministry of Health

bayer israel ltd - loratadine; pseudoephedrine sulfate - טבליות בשחרור ממושך - loratadine 5 mg; pseudoephedrine sulfate 120 mg - loratadine - loratadine - relief of symptoms of seasonal allergic rhinitis when both the antihistaminic properties and the nasal decongestant activity are desired.

ישראל - עברית - Ministry of Health

bayer israel ltd - loratadine - טבליה - loratadine 10 mg - other antihistamines for systemic use - seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.

ישראל - עברית - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose 250 iu/vial - powder for solution for injection - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.